See more : Kongsberg Gruppen ASA (NSKFF) Income Statement Analysis – Financial Results
Complete financial analysis of Ayurcann Holdings Corp. (AYURF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ayurcann Holdings Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Brambles Limited (BXBLY) Income Statement Analysis – Financial Results
- CBRE Acquisition Holdings, Inc. (CBAH) Income Statement Analysis – Financial Results
- Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SS) Income Statement Analysis – Financial Results
- Gemina Laboratories Ltd. (GLABF) Income Statement Analysis – Financial Results
- KKR Acquisition Holdings I Corp. (KAHC-UN) Income Statement Analysis – Financial Results
Ayurcann Holdings Corp. (AYURF)
About Ayurcann Holdings Corp.
Ayurcann Holdings Corp. provides post-harvest outsourcing solutions to licensed cannabis producers in Canada. The company offers end-to-end outsourcing solutions, including extraction and refinement, bulk distillate oil sales, formulation and white label manufacturing, and fulfillment and distribution, as well as customized packaging solutions and inventory management services. It also provides medicinal cannabis, such as tincture, vapes, and topicals. In addition, the company operates Ayurcann marketplace, an online cannabis market for medical cannabis consumers. The company was founded in 2018 and is headquartered in Pickering, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 12.49M | 9.39M | 7.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.81M | 7.17M | 3.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.68M | 2.22M | 4.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 29.46% | 23.66% | 60.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.73M | 5.51M | 2.46M | 0.00 | 196.35K | 218.31K | 209.44K | 324.34K | 261.05K | 411.27K | 610.67K | 101.68K | 0.00 |
| Selling & Marketing | 2.49M | 0.00 | 0.00 | 0.00 | 0.00 | 1.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.22M | 5.51M | 2.46M | 244.78K | 196.35K | 218.31K | 209.44K | 324.34K | 261.05K | 411.27K | 610.67K | 101.68K | 6.80K |
| Other Expenses | 66.67K | 0.00 | 101.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.67M | 5.52M | 2.47M | 244.78K | 239.96K | 284.75K | 209.44K | 324.34K | 261.05K | 411.27K | 610.67K | 101.68K | 6.80K |
| Cost & Expenses | 17.48M | 12.68M | 5.47M | 244.78K | 239.96K | 284.75K | 209.44K | 324.34K | 261.05K | 411.27K | 610.67K | 101.68K | 6.80K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 30.19K | 91.15K | 315.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 779.65K | 779.65K | 320.79K | 281.72K | 171.86K | 161.14K | 52.52K | -9.59K | 11.57K | 4.45M | 90.20K | 0.00 | 0.00 |
| EBITDA | -4.14M | -2.97M | 2.54M | -244.78K | -257.10K | -296.73K | -219.03K | -335.07K | -249.47K | 4.04M | -520.47K | -101.68K | -6.80K |
| EBITDA Ratio | -33.18% | -31.68% | 33.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.34M | -3.33M | 2.16M | -244.78K | -257.10K | -296.73K | -209.44K | -324.34K | -261.05K | -411.27K | -610.67K | -101.68K | -6.80K |
| Operating Income Ratio | -42.78% | -35.50% | 28.29% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -285.85K | -37.53K | -1.79M | 7.84K | 17.14K | 11.98K | 9.59K | 10.73K | -11.86K | -4.46M | -98.95K | 0.00 | 0.00 |
| Income Before Tax | -5.31M | -3.42M | 57.09K | -236.94K | -222.82K | -272.77K | -199.84K | -313.61K | -272.90K | -4.87M | -709.61K | -101.68K | 0.00 |
| Income Before Tax Ratio | -42.48% | -36.47% | 0.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 96.85K | -335.45K | 335.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -102.77K | -486.63K | -239.64K | 0.00 | 6.80K |
| Net Income | -5.31M | -3.09M | -278.36K | -236.94K | -222.82K | -272.77K | -199.84K | -313.61K | -170.13K | -4.38M | -469.97K | -101.68K | -6.80K |
| Net Income Ratio | -42.48% | -32.90% | -3.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.04 | -0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.02 | -0.40 | -0.04 | -0.21 | -0.01 |
| EPS Diluted | -0.04 | -0.03 | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.02 | -0.40 | -0.04 | -0.21 | -0.01 |
| Weighted Avg Shares Out | 150.12M | 118.51M | 84.99M | 15.86M | 15.86M | 14.29M | 10.86M | 10.86M | 10.86M | 10.86M | 10.86M | 494.67K | 649.94K |
| Weighted Avg Shares Out (Dil) | 150.12M | 118.51M | 84.99M | 15.86M | 15.86M | 14.29M | 10.86M | 10.86M | 10.86M | 10.86M | 10.86M | 494.67K | 649.94K |
AYURCANN REPORTS ANOTHER RECORD SALES GROWTH IN Q1 2025 OF $14,760,268 AND PROVIDES CORPORATE UPDATE
Toronto, Ontario, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF) (“Ayurcann” or the “Company”), a leading Canadian processing and manufacturing company specializing in cannabis 2.0 and 3.0 products, is pleased to announce its financial and...
AYURCANN TERMINATES BUSINESS COMBINATION
Toronto, Ontario, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF) (“Ayurcann” or the “Company”), a leading Canadian processing and manufacturing company specializing in cannabis 2.0 and 3.0 products, announces that, further to its press releases...
AYURCANN REPORTS FISCAL YEAR 2024 RECORD SALES OF $45,265,235 IN GROSS REVENUE, FEATURING ANOTHER 100% YEAR-OVER-YEAR INCREASE
Toronto, Ontario, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian processing and manufacturing company specializing in cannabis 2.0 and 3.0 products, is pleased to announce its...
Ayurcann Holdings Corp is entering into a business combination with Arogo Capital Acquisition Corp. and its subsidiaries at a combined enterprise value estimated to be U.S. $210 million.
Ayurcann is an award-winning Canadian cannabis extraction company that specializes in the processing and manufacturing of cannabis 2.0 and 3.0 products:
AYURCANN REPORTS RECORD SALES IN Q3 2024 OF $11,655,360 FEATURING A 97% INCREASE IN GROSS REVENUE
Toronto, Ontario, May 27, 2024 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company specializing in the processing and manufacturing of various cannabis 2.0 and 3.0 products...
AYURCANN REPORTS RECORD SALES IN Q2 2024 FEATURING A 141% INCREASE IN GROSS REVENUE
Toronto, Ontario, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company specializing in the processing and manufacturing of various derivative cannabis 2.0 and 3.0...
Ayurcann Provides a Corporate Update, Completes Debt Settlement and Grants Options and RSUs
Pickering, Ontario, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to...
AYURCANN ANNOUNCES AGSM RESULTS
Toronto, Ontario, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company, specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to...
AYURCANN REPORTS RECORD SALES IN Q1 2024 FEATURING A 249% INCREASE IN GROSS REVENUE
Toronto, Ontario, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company specializing in the processing and manufacturing of various derivative cannabis 2.0 and 3.0...
AYURCANN REPORTS 2023 FINANCIAL RESULTS FEATURING $22,371,604 IN GROSS REVENUE
Toronto, Ontario, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Ayurcann Holdings Corp. (CSE: AYUR, OTCQB: AYURF, FSE: 3ZQ0) (“Ayurcann” or the “Company”), a leading Canadian cannabis extraction company specializing in the processing and co-manufacturing of pharma grade cannabis and hemp to...
Source: https://incomestatements.info
Category: Stock Reports